DDInter1220 DDInter899
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia, although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Milnacipran {u} (Compound) resembles {v} (Compound) Meperidine
Milnacipran {u} (Compound) binds {v} (Gene) SLC6A4
Milnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Milnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Milnacipran {u} (Compound) causes {v} (Side Effect) Migraine
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Milnacipran {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Milnacipran {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Milnacipran (Compound) resembles Levomilnacipran (Compound)
Milnacipran (Compound) resembles Meperidine (Compound)
Milnacipran (Compound) binds SLC6A4 (Gene)
Milnacipran (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Milnacipran (Compound) downregulates GJA1 (Gene)
Milnacipran (Compound) causes Migraine (Side Effect)
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Milnacipran may lead to a major life threatening interaction when taken with Phentermine
Milnacipran may lead to a major life threatening interaction when taken with Teriflunomide